1. Home
  2. ZD vs MYGN Comparison

ZD vs MYGN Comparison

Compare ZD & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZD
  • MYGN
  • Stock Information
  • Founded
  • ZD 1995
  • MYGN 1991
  • Country
  • ZD United States
  • MYGN United States
  • Employees
  • ZD N/A
  • MYGN N/A
  • Industry
  • ZD Advertising
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • ZD Consumer Discretionary
  • MYGN Health Care
  • Exchange
  • ZD Nasdaq
  • MYGN Nasdaq
  • Market Cap
  • ZD 2.0B
  • MYGN 2.0B
  • IPO Year
  • ZD 1999
  • MYGN 1995
  • Fundamental
  • Price
  • ZD $56.65
  • MYGN $17.41
  • Analyst Decision
  • ZD Buy
  • MYGN Buy
  • Analyst Count
  • ZD 8
  • MYGN 12
  • Target Price
  • ZD $71.50
  • MYGN $28.18
  • AVG Volume (30 Days)
  • ZD 441.8K
  • MYGN 874.8K
  • Earning Date
  • ZD 11-07-2024
  • MYGN 11-07-2024
  • Dividend Yield
  • ZD N/A
  • MYGN N/A
  • EPS Growth
  • ZD 41.53
  • MYGN N/A
  • EPS
  • ZD 1.38
  • MYGN N/A
  • Revenue
  • ZD $1,378,750,000.00
  • MYGN $823,600,000.00
  • Revenue This Year
  • ZD $7.04
  • MYGN $13.95
  • Revenue Next Year
  • ZD $6.10
  • MYGN $9.71
  • P/E Ratio
  • ZD $41.17
  • MYGN N/A
  • Revenue Growth
  • ZD 0.58
  • MYGN 12.15
  • 52 Week Low
  • ZD $37.76
  • MYGN $16.00
  • 52 Week High
  • ZD $70.90
  • MYGN $29.30
  • Technical
  • Relative Strength Index (RSI)
  • ZD 77.70
  • MYGN 21.54
  • Support Level
  • ZD $48.01
  • MYGN $16.86
  • Resistance Level
  • ZD $51.03
  • MYGN $18.57
  • Average True Range (ATR)
  • ZD 1.58
  • MYGN 1.12
  • MACD
  • ZD 0.85
  • MYGN -0.37
  • Stochastic Oscillator
  • ZD 85.90
  • MYGN 8.94

About ZD Ziff Davis Inc.

Ziff Davis Inc is a focused digital media and internet company whose portfolio includes brands in technology, entertainment, shopping, health, cybersecurity, and martech. It has two reportable segments: Digital Media and Cybersecurity and Martech. The company's brands include Mashable, Ookla, Offers.com, IGN, and VPN among others. The majority of revenue is generated from Digital Media.

About MYGN Myriad Genetics Inc.

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Share on Social Networks: